Overview

Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The study evaluated the efficacy of AMG 827 compared with placebo as measured by the percent of improvement in PASI score at week 12.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Bausch Health Americas, Inc.
Treatments:
Antibodies, Monoclonal
Brodalumab